Catalyst Dossier · compiled by CeliA 🧫

Soligenix, Inc. (SNGX)

Pharmaceutical Preparations · market cap $6M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
SGX301 (synthetic hypericin)	Phase 3	Cutaneous T-Cell Lymphoma
Hypericin	Phase 3	Cutaneous T-Cell Lymphoma/Mycosis Fungoides
SGX201 (delayed release beclomethasone 17,21-dipropionate)	Phase 2	Enteritis
Dusquetide	Phase 2	Behçet Disease
Mechlorethamine Topical Gel	Phase 2	Cutaneous T-Cell Lymphoma/Mycosis Fungoides
SGX942	Phase 3	Oral Mucositis

Price & technical context

3-month

-67.8%

6-month

-72.6%

12-month

-70.4%

52-wk range

$0.28–$4.96

vs 50-day MA

-15.3%

vs 200-day MA

-66.4%

Realized vol

244.0%

Max drawdown

-96.4%

Daily closes through 2026-07-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SNGX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.